Terms: = Lung cancer AND RALGDS, FLJ20922, 5900, ENSG00000160271, RalGEF, RGF, Q12967 AND Treatment
5 results:
1. Coexistence of sensitive and resistant epidermal growth factor receptor (EGFR) mutations in pretreatment non-small cell lung cancer (NSCLC) patients: First or third generation tyrosine kinase inhibitors (TKIs)?
Zhang B; Xu J; Zhang X; Gu P; Wang H; Wang S; Qian J; Qiao R; Zhang Y; Yang W; Qian F; Zhou Y; Lu J; Zhang L; Han B
Lung Cancer; 2018 Mar; 117():27-31. PubMed ID: 29496252
[TBL] [Abstract] [Full Text] [Related]
2. Preclinical rationale for combining an EGFR antibody with cisplatin/gemcitabine for the treatment of NSCLC.
Samakoglu S; Deevi DS; Li H; Wang S; Murphy M; Bao C; Bassi R; Prewett M; Tonra JR
Cancer Genomics Proteomics; 2012; 9(2):77-92. PubMed ID: 22399498
[TBL] [Abstract] [Full Text] [Related]
3. Strontium-89 chloride (Metastron) for palliative treatment of bony metastases. The University of Minnesota experience.
Lee CK; Aeppli DM; Unger J; Boudreau RJ; Levitt SH
Am J Clin Oncol; 1996 Apr; 19(2):102-7. PubMed ID: 8610630
[TBL] [Abstract] [Full Text] [Related]
4. Results of radical radiation therapy in clinical stage I, technically operable non-small cell lung cancer.
Haffty BG; Goldberg NB; Gerstley J; Fischer DB; Peschel RE
Int J Radiat Oncol Biol Phys; 1988 Jul; 15(1):69-73. PubMed ID: 2839443
[TBL] [Abstract] [Full Text] [Related]
5. The characteristics of long-term survivors of lung cancer treated with radiation.
Sherman DM; Weichselbaum R; Hellman S
Cancer; 1981 Jun; 47(11):2575-80. PubMed ID: 6266635
[TBL] [Abstract] [Full Text] [Related]
